Alto Neuroscience, Inc. ANRO 深 滬
已收盤 04-02 16:00:00 美东时间
21.68
-1.730
-7.39%
華盛通- 最 高22.95
- 今 開20.00
- 成交量 71.05万股
- 最 低 19.49
- 昨 收 23.41
- 總市值 6.93亿
- 52周最高 25.17
- 市盈率 靜 --
- 換手率 2.22%
- 52周最低 2.02
- 委 比 -33.33%
- 總股本 3194.55万
- 歷史最高 25.17
- 量 比 1.99
- 振 幅 14.78%
- 歷史最低 1.60
- 每 手 1
- 風險率 7.16%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Alto Neuroscience shares are trading lower after the company announced topline data from its Phase 2 proof-of-concept clinical trial evaluating ALTO-101 did not achieve statistical significant on primary electroencephalography or cognitive endpoints versus placebo.
Alto Neuroscience shares are trading lower after the company announced topline ...
04-02 04:34
Alto Neuroscience Announces Topline Data From Phase 2 POC Clinical Trial Evaluating ALTO-101 For Treatment Of CIAS; ALTO-101 Did Not Achieve Statistical Significance On Primary EEG Or Cognitive Endpoints Versus Placebo
— In the proof-of-concept study, ALTO-101 did not achieve statistical significance on primary endpoint; signals observed across EEG measures including near-significant improvement in theta-ITC (p=0.052) —— Alto has
04-02 04:32
美股大行评级 | 超多下调！露露乐蒙、Oklo、腾讯音乐、Docusign、BOBS、Bicycle、Academy Sports等遭多家大行下调目标价
今日重点评级关注：花旗：维持Candel Therapeutics"买入"评级，目标价从22美元升至26美元；Chardan Capital：维持CervoMed"买入"评级，目标价从15美元升至21美元
03-19 14:31
美股大行评级 | 摩根大通上调哔哩哔哩至"超配"，目标价从27美元升至35美元；Rhythm遭花旗、大摩等多家机构下调目标价
今日重点评级关注：韦德布什：维持Black Diamond Therapeutic"跑赢大市"评级，目标价从13美元升至14美元；花旗：维持Olema Pharmaceuticals"买入"评级，目标价从60美元升至62美元
03-18 10:48
Earnings Scheduled For March 16, 2026
Companies Reporting Before The Bell • CytomX Therapeutics (NASDAQ:CTMX) is expe...
03-16 19:11
Alto Neuroscience Enters Into Securities Purchase Agreement To Sell Securities In Private Placement Financing For Gross Proceeds Of ~$120M
– Financing led by Commodore Capital with participation from new and existing biotech focused investors –– Alto expects to use the proceeds of the financing to support the development of ALTO-207 in Treatment
03-16 19:11
Alto Neuroscience Q4 EPS $(0.45) Beats $(0.55) Estimate
Alto Neuroscience (NYSE:ANRO) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.55) by 18.77 percent. This is a 19.64 percent increase over losses of $(0.56) per share from
03-16 18:26
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Zevra Therapeutics (NASDAQ:ZVRA) stock moved upwards by 20.6% to $11.0...
03-10 05:05
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders
Issued on behalf of Helus Pharma VANCOUVER, BC, Feb. 26, 2026 /PRNewswire/ -- USA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 results in treatm...
02-27 01:07
美股大行评级 | 潜在涨幅1226.53%！RenovoRx获Ascendiant Capital升目标价至13美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从12.5美元升至13美元；Lake Street：维持Insight Molecular"买入"评级，目标价从8美元升至12美元
02-18 16:48
